The microwave and temperature sensitive
liposomes were fabricated successfully from 1,2-dipalmityol-sn-glycero-3-phosphocholine (DPPC),
cholesterol, and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(
polyethylene glycol)-2000 (DSPE-PEG2000) with a molar ratio of 4:1:0.26 by co-encapsulating NaCl and
doxorubicin (DOX) through the thin-film hydration method to externally manipulate drug release at a predetermined location in the body at a desired time in the right dosage for combination microwave
hyperthermia and
chemotherapy of
cancer to afford a synergistic
therapeutic effect. It was found that the confinement of the high concentration of NaCl
ions inside the small size of the
liposomes led to a more-rapid temperature elevation than the dissociative
ions upon microwave treatment. More than 67.6%
doxorubicin was released from the DOX and NaCl co-loaded
liposomes (DOX&NaCl@
liposomes) upon microwave irradiation for 2 min. After incubation with 2 mg/mL DOX&NaCl@
liposomes for 4 h followed by treatment with microwave for 2 min, the inhibition rate of human
breast cancer cell MDA-MB-231 was evaluated as 76.1%, much higher than that for NaCl@
liposomes (29.8%) and DOX@
liposomes (40.2%). The
tumor growth inhibition was evaluated to be 73.4% after
intravenous injection of DOX&NaCl@
liposomes followed by microwave irradiation, much higher than that with only NaCl@
liposomes (41.5%) or DOX@
liposomes (45.5%) combined with microwave irradiation. Therefore, DOX&NaCl@
liposomes could serve as a promising thermochemotherapy nanomedicine for
cancer treatment because of its excellent microwave susceptible property and good biocompatibility.